Pete Wildes

VP, Cancer Biology at REVOLUTION Medicines

Pete is enthusiastic about applying rigorous, collaborative scientific inquiry to enable successful drug discovery and development. He has a multidisciplinary background in biochemistry, protein engineering, and chemical biology, and broad experience in the biotech industry, having previously worked in protein engineering for the industrial biotech sector, as head of the Biochemistry department at Dupont Industrial Biosciences.

Pete joined Revolution Medicines in 2015 and has been a major contributor to the pipeline, including developing screening programs to support discovery of RMC-4630 and RMC-5552, and leading an integrated, multidisciplinary approach incorporating chemical biology, biochemistry, and cell biology to support discovery and development of the tri-complex RAS inhibitor programs. He built a world-class in vitro biology program that has been key to understanding the unique mechanisms of the tri-complex RAS inhibitor platform, and the intricacies of RAS biology that underly the right choice of RAS inhibitors and companions for translation to the clinic.

Pete graduated from Cornell University with a BA in Biology and received his Ph.D. in Molecular and Cell Biology from UC Berkeley working in the laboratory of Susan Marqusee. He also conducted postdoctoral research with Jim Wells at UCSF. Pete is a co-author/inventor on multiple scientific publications and patent applications.


Previous companies

DuPont logo
UC Berkeley logo


  • VP, Cancer Biology

    Current role